Formulations comprising heterocyclic protein kinase inhibitors

Abstract

Provided is a composition comprising a polyglycolized glyceride and a compound having the following structure (I):or a pharmaceutically acceptable salt thereof. Also provided are crystalline forms of the compound of structure (I), or a pharmaceutically acceptable salt thereof. Methods of making the same, and methods for using the same in the treatment of cancer, autoimmune, inflammatory and other Pim kinase-associated diseases, disorders or conditions are also disclosed.

1 .- 168 . (canceled) 
     
     
         169 . A crystalline form of a maleic acid salt or a methanesulfonic acid salt of a compound of structure (I): 
       
         
           
           
               
               
           
         
       
     
     
         170 . The crystalline form of  claim 169 , wherein the maleic acid salt of the compound of structure (I) is characterized by an X-ray powder diffraction pattern substantially in accordance with the maleic acid salt shown in  FIG.  19 A . 
     
     
         171 . The crystalline form of  claim 169 , wherein the maleic acid salt of the compound of structure (I) has a differential scanning calorimetry thermogram substantially in accordance with that shown in  FIG.  19 B . 
     
     
         172 . The crystalline form of  claim 171 , wherein the differential scanning calorimetry thermogram having an endothermic event from about 174.3° C. to about 177.6° C. 
     
     
         173 . The crystalline form of  claim 169 , wherein the maleic acid salt of the compound of structure (I) has a melting point temperature of about 174.3° C. 
     
     
         174 . The crystalline form of  claim 169 , wherein the maleic acid salt of the compound of structure (I) has a thermogravimetric analysis characterized by a mass loss of about 4.69% when heated from about 117.4° C. to about 180.3° C. 
     
     
         175 . The crystalline form of  claim 169 , wherein the maleic acid salt of the compound of structure (I) has a thermogravimetric analysis diagram substantially in accordance with that shown in  FIG.  19 C . 
     
     
         176 . The crystalline form of  claim 169 , wherein the methanesulfonic acid salt of the compound of structure (I) is characterized by an X-ray powder diffraction pattern substantially in accordance with the methanesulfonic acid salt shown in  FIG.  20 A . 
     
     
         177 . The crystalline form of  claim 169 , wherein the methanesulfonic acid salt of the compound of structure (I) has a differential scanning calorimetry thermogram substantially in accordance with that shown in  FIG.  20 B . 
     
     
         178 . The crystalline form of  claim 177 , wherein the differential scanning calorimetry thermogram having an endothermic event from about 206.3° C. to about 207.5° C. 
     
     
         179 . The crystalline form of  claim 169 , wherein the methanesulfonic acid salt of the compound of structure (I) has a melting point temperature of about 206.3° C. 
     
     
         180 . The crystalline form of  claim 169 , wherein the methanesulfonic acid salt of the compound of structure (I) has a thermogravimetric analysis characterized by a mass loss of about 4.95% when heated from about 117.6° C. to about 212.7° C. 
     
     
         181 . The crystalline form of  claim 169 , wherein the methanesulfonic acid salt of the compound of structure (I) has a thermogravimetric analysis diagram substantially in accordance with that shown in  FIG.  20 C . 
     
     
         182 . The crystalline form of  claim 169 , wherein the crystalline form is substantially pure. 
     
     
         183 . The crystalline form of  claim 182 , wherein the crystalline form is 99.35% pure. 
     
     
         184 .- 186 . (canceled) 
     
     
         187 . A method for treating a cancer comprising administering a therapeutically effective amount of the crystalline form of  claim 169 , wherein the cancer is bladder cancer, prostate cancer, colorectal cancer, a hematological malignancy, acute myeloid leukemia, a Pim kinase-mediated cancer, or a fibrotic cancer. 
     
     
         188 . (canceled)